DSIP (5mg)

DSIP (Delta Sleep-Inducing Peptide)

Delta Sleep-Inducing Peptide, or DSIP, is a naturally-occurring peptide made of nine amino acids, isolated from the central nervous system of experimental models of electrically induced sleep. DSIP is posited to regulate the sleep cycle, as suggested by its name, but may also play a role in regulating various physiological processes. Suggested to induce delta sleep in test models, this neuropeptide also appears to impact electrophysiological activity and possibly regulate the neurotransmitter levels in the brain.⁽¹⁾

DSIP peptide was first characterized and examined from 1963 to 1977 and has since been widely studied by scientists.⁽²⁾ Initially regarded only for its potential as a sleep-including factor, DSIP was soon suggested to induce other potential actions, such as mitigating pain, sleep cycle regulation, and mitigating withdrawal.⁽³⁾

Mechanisms of Action

DSIP is believed to have the potential to modify the structure and quality of sleep by engaging with the central nervous system. It is thought that DSIP may potentially reduce the time it takes to fall asleep and enhance the overall quality of sleep by influencing the activity of various neurotransmitters within the brain. Despite these possibilities, scientific research has yet to definitively identify the primary mechanisms and pathways through which DSIP exerts its actions. However, it is hypothesized that DSIP may target several specific receptors, which are considered crucial in its function. These include:

• N-methyl-D-aspartate (NMDA) receptors and gamma-aminobutyric acid (GABA) receptors: NMDA receptors are linked to glutamate, a vital neurotransmitter that facilitates brain excitation, while GABA receptors are associated with inhibitory neurotransmission, playing a significant role in calming the brain. Research conducted on murine models has suggested that DSIP might amplify GABA’s calming actions, which assists in reducing brain activity and helps individuals fall asleep more easily. Concurrently, murine studies suggest that DSIP may dampen some of the stimulatory impacts of NMDA receptors, thereby decreasing overall brain stimulation and further aiding in sleep promotion.⁽⁴⁾⁽⁵⁾
• Opioid receptors: Further research indicates that DSIP might indirectly affect opioid receptors in the brain. This interaction is believed to influence the peptide’s ability to modulate sleep and alleviate withdrawal symptoms, highlighting its complex involvement in the brain’s signaling systems.⁽⁶⁾⁽⁷⁾
• Alpha 1-adrenergic receptor: This receptor, apparently found in the pineal gland, has been another focus of DSIP research. An experimental study has suggested that DSIP’s modulation of the alpha 1-adrenergic receptor could be a mechanism through which it affects sleep patterns. This interaction also hints at DSIP’s potential role in managing stress tolerance, given the significant influence of alpha 1-adrenergic signaling in stress-related processes.⁽⁸⁾

These findings underline the complex and multifaceted ways in which DSIP might influence sleep and stress management, although more research is needed to understand its mechanisms of action.

Chemical Makeup

Molecular Formula: C₃₅H₄₈N₁₀O₁₅
Molecular Weight: 848.82 g/mol
Other Known Titles: DSIP nonapeptide; emideltide

Research and Clinical Studies

DSIP and Sleep Cycles

A study⁽⁹⁾ was conducted on feline models to examine the potential action of DSIP on sleep patterns. The models were divided into two groups; one was a control, and the other was labeled as the DSIP group. The peptide was presented to the cats and was monitored for 8 hours. Results indicated that there appeared to be a significant increase in total sleep and slow wave sleep (SWS) in the DSIP group. The action of DSIP appeared to be immediate as the amount of SWS sleep elevated within the first hour following study initiation. This increase appeared to be maintained for 7 hours and then decreased in the eighth hour. SWS, often called deep sleep, is suggested as one of the core stages within sleep architecture, broadly categorized into non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. The overall structure of sleep is typically cyclic, alternating between NREM and REM stages multiple times. Apparently, SWS falls under the NREM category and scientists detect it by its low-frequency, high-amplitude delta waves evident in electroencephalogram (EEG) recordings. Sleep begins with NREM sleep, subdivided into three stages: N1, N2, and N3. N1 and N2 are lighter stages of sleep, while N3, synonymous with SWS, is the deepest stage of sleep. Following the deep sleep stage, the cycle progresses into REM sleep, where brain activity increases and dreams occur.

A clinical study⁽¹⁰⁾ has suggested that the peptide may lead to an immediate increase in sleep pressure and resulted in a 59% increase in sleep within two hours of initiating DSIP experimentation. The scientists also posited that the peptide may have enhanced sleep efficiency, potentially by shortening sleep onset.⁽¹⁰⁾

DSIP and Endocrine Regulation

DSIP has been posited to interact with certain hormonal messengers typically released during sleep. Examples may include the luteinizing hormone (LH), which is considered a crucial hormone in the regulation of reproductive hormones such as testosterone. In a study with murine models,⁽¹¹⁾ DSIP was examined for its potential actions on the endocrine system. Within 30 minutes, it was noted that the levels of LH appeared to be significantly elevated, whereas there was no perceived impact on another regulatory messenger called follicle-stimulating hormone (FSH).

Further studies have suggested that DSIP may lead to increased secretion of growth hormone, positing that the peptide may potentially act on the hypothalamus to regulate hormonal secretion. Utilizing ovariectomized murine models to exclude the actions of gonadal steroids, the research observed an apparent elevation in GH levels caused by DSIP. The potential involvement of a dopaminergic mechanism in this process was inferred from the blocking action of pimozide, a dopamine antagonist, on the DSIP-induced GH increase. Additionally, in vitro studies with pituitary cells suggest a similar increase in GH release upon exposure to DSIP, albeit with a notable decline at higher concentrations. This pattern hints at the complex nature of DSIP’s role in GH regulation, potentially linking it to sleep-induced GH release, given the peptide’s association with slow-wave sleep patterns and the apparent correlation of such sleep phases with GH secretion.⁽¹²⁾

DSIP and Stress Response

Researchers have investigated the potential action of DSIP on murine models subjected to experimentally induced stress.⁽¹³⁾ The murine models were divided into six groups, where the control group was presented with a placebo and the rest with DSIP. The six groups included (i) control group, (ii) stress group, (iii) group with DSIP one hour before stress experiments, (iv) DSIP 24 hours before stress experiments, (v) DSIP one hour before the last stress experiment and (vi) DSIP 24 hours before the last stress experiment. This research primarily focused on assessing changes in substance P, beta-endorphin, and corticosterone levels, which are critical in understanding the stress response and potential modulatory impacts of DSIP. Initial findings highlighted that DSIP exposure might induce noticeable fluctuations in the levels of these markers, suggesting a possible stress-modulatory role. For instance, there was an initial decrease followed by a dramatic increase in beta-endorphin. This pattern suggests DSIP’s potential influence on the opioidergic system, possibly contributing to mechanisms of stress mitigation or adaptation. Regarding corticosterone levels, which directly indicate stress in murine models, a decrease was noted shortly after DSIP exposure. The study posits that DSIP’s actions on substance P, beta-endorphin, and corticosterone levels are part of a broader spectrum of biochemical changes, hinting that DSIP might initiate a series of molecular reactions contributing to its stress-modulatory actions.⁽¹³⁾

DSIP and Longevity

A study⁽¹⁴⁾ was conducted on murine models, equally divided into DSIP and control groups. The researchers suggested that DSIP did not appear to influence food intake, however, it did apparently decrease the weight of the murine models. It appeared to decrease the chromosomal aberrations in the bone marrow by 23% and improve the life span by 24% compared to the control group. Moreover, DSIP also appeared to lead to a 2.5-fold decrease in the occurrence of malignancies.

Another study suggests that the apparent protective actions of DSIP may be due to the potential antioxidative properties of the peptide. The study⁽¹⁵⁾ was conducted on murine models, and the researchers posited that DSIP may inhibit the levels of malonic dialdehyde in the models. Malonic dialdehyde is a byproduct of lipid peroxidation, and increased levels of malonic dialdehyde typically induce increased oxidative stress. This suggested that DSIP may prevent lipid peroxidation in the murine models, which may execute antioxidant properties. DSIP may also stimulate the endogenous antioxidant system, influencing various enzymatic levels. The researchers commented that “DSIP exerts stimulating influence upon the superoxid-dismutese, catalase, ceruloplasmin activities as well as the level of nonenzymatic antioxidants–urea and uric acids, because during organism aging the antioxidant defense systems are being suppressed. DSIP increases the volume of tissues and blood endogenous antioxidant defense system mainly by means of enzymatic antioxidant system, especially during later ontogenesis.”⁽¹⁵⁾

DSIP is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

References:

1. National Center for Biotechnology Information. “PubChem Compound Summary for CID 3623358, Emideltide;delta Sleep Inducing Peptide” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/3623358
2. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986 Nov-Dec;7(6):1165-87. https://pubmed.ncbi.nlm.nih.gov/3550726/
3. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006 Apr;97(2):303-9. https://pubmed.ncbi.nlm.nih.gov/16539679/
4. Grigor’ev VV, Ivanova TA, Kustova EA, Petrova LN, Serkova TP, Bachurin SO. Effects of delta sleep-inducing peptide on pre- and postsynaptic glutamate and postsynaptic GABA receptors in neurons of the cortex, hippocampus, and cerebellum in rats. Bull Exp Biol Med. 2006 Aug;142(2):186-8. English, Russian. doi: 10.1007/s10517-006-0323-9. PMID: 17369935
5. Sudakov KV, Umriukhin PE, Rayevsky KS. Delta-sleep inducing peptide and neuronal activity after glutamate microiontophoresis: the role of NMDA-receptors. Pathophysiology. 2004 Oct;11(2):81-86. https://pubmed.ncbi.nlm.nih.gov/15364118/
6. Nakamura A, Nakashima M, Sakai K, Niwa M, Nozaki M, Shiomi H. Delta-sleep-inducing peptide (DSIP) stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro. Brain Res. 1989 Feb 27;481(1):165-8. doi: 10.1016/0006-8993(89)90498-8. PMID: 2706459.
7. Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology. 1983;10(4):205-8. doi: 10.1159/000118012. PMID: 6328354.
8. Graf MV, Schoenenberger GA. Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. J Neurochem. 1987 Apr;48(4):1252-7. doi: 10.1111/j.1471-4159.1987.tb05654.x. PMID: 3029331.
9. Susić V, Masirević G, Totić S. The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat. Brain Res. 1987 Jun 30;414(2):262-70. https://pubmed.ncbi.nlm.nih.gov/3620931/
10. Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):341-5. https://pubmed.ncbi.nlm.nih.gov/6895513/
11. Iyer KS, McCann SM. Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat. Brain Res Bull. 1987 Nov;19(5):535-8. doi: 10.1016/0361-9230(87)90069-4. https://pubmed.ncbi.nlm.nih.gov/3121137/
12. Iyer KS, McCann SM. Delta sleep-inducing peptide (DSIP) stimulates growth hormone (GH) release in the rat by hypothalamic and pituitary actions. Peptides. 1987 Jan-Feb;8(1):45-8. doi: 10.1016/0196-9781(87)90163-x. PMID: 3575154.
13. Sudakov KV, Coghlan JP, Kotov AV, Salieva RM, Polyntsev YuV, Koplik EV. Delta-sleep-inducing peptide sequels in the mechanisms of resistance to emotional stress. Ann N Y Acad Sci. 1995 Dec 29;771:240-51. https://pubmed.ncbi.nlm.nih.gov/8597403/
14. Popovich IG, Voitenkov BO, Anisimov VN, Ivanov VT, Mikhaleva II, Zabezhinski MA, Alimova IN, Baturin DA, Zavarzina NY, Rosenfeld SV, Semenchenko AV, Yashin AI. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev. 2003 Jun;124(6). https://pubmed.ncbi.nlm.nih.gov/12782416/
15. Bondarenko TI, Maĭboroda EA, Mikhaleva II, Prudchenko IA. [Mechanism of delta-sleep inducing peptide geroprotective activity]. Adv Gerontol. 2011;24(1):80-92. Russian. https://pubmed.ncbi.nlm.nih.gov/21809625/